$CBIO Cashflow Statement | Understand Stock

$CBIO

$12.76 -$0.06 (0.47%) Close

$CBIO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Related Party
Total share-based compensation expense
Research and development license expense
Depreciation expense
Loss on disposal of property and equipment
Asset impairment
Non-cash interest expense
Related Party
Total non-cash interest expense
Non-cash research and development expense related to Paragon option agreement
Non-cash lease expense
Issuance of common stock for services
Changes in operating assets and liabilities
Accounts payable
Nonrelated Party
Total accounts payable
Accrued expenses
Lease liabilities
Accrued expenses and other current liabilities
Related Party
Total accrued expenses and other current liabilities
Related party accounts payable and other current liabilities
Deferred revenue
Deposit liability
Operating lease liability
Accounts receivable
Prepaid expenses and other current assets
Prepaid research and development expenses
Other assets
Net cash used in operating activities
Cash flows from investing activities:
Purchase of research and development license
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from the Pre-Closing Financing, net
Proceeds from the private placement financing, net
Cash acquired in connection with the reverse recapitalization
Proceeds from early exercise of options
Proceeds from issuance of common stock
Proceeds from exercise of stock options
Proceeds from issuance of Series Seed convertible preferred stock
Proceeds from the issuance of notes payable, net of issuance costs
Related Party
Total proceeds from the issuance of notes payable, net of issuance costs
Payment of deferred offering costs
Repurchase of equity awards
Net cash provided by financing activities
Net increase in cash, cash equivalents, and restricted cash
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosure of non-cash operating and financing activities:
Operating lease liability arising from obtaining operating right-of-use asset
Assets acquired in connection with the reverse recapitalization
Other liabilities assumed in connection with the reverse recapitalization
Purchases of property and equipment included in accounts payable and accrued expenses
Deferred financing costs included in accounts payable and accrued expenses
Convertible note principal and non-cash accrued interest converted to ordinary shares
Non-cash exchange of Pre-Merger Crescent Series Seed Preferred Stock for Series A Non-Voting Convertible Preferred Shares

Comments